Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H13FN2O5 |
Molecular Weight | 259.2216 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2[18F])C(=O)NC1=O
InChI
InChIKey=GBBJCSTXCAQSSJ-HMQZJZAASA-N
InChI=1S/C10H13FN2O5/c1-4-2-13(10(17)12-8(4)16)9-6(11)7(15)5(3-14)18-9/h2,5-7,9,14-15H,3H2,1H3,(H,12,16,17)/t5-,6+,7-,9-/m0/s1/i11-1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15586282
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15586282
Clevudine F18 is a radioconjugate comprised of the synthetic pyrimidine analog clevudine (1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine, d-FMAU) labeled with the radioisotope fluorine F18. Upon administration, fluorine F18 clevudine is distributed and taken up by cells based on the rate of the cell’s DNA synthesis. The amount is then measured using positron emission tomography (PET). The compound is investigated as an imaging agent in prostate, breast cancers, and other malignant neoplasms.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map03030 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15586282 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis of 2'-deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. | 2003 Apr |
|
Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. | 2004 Apr |
|
Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. | 2005 Jan |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15586282
A dose of 355-385 MBq of [18F]FMAU was intravenously infused into patients over 60s.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15296672
Breast cancer cells were transduced with herpes simplex virus 1 thymidine kinase. Logarithmically growing cells were incubated with about 111 –148 KBq (3 - 4 uCi) of [18F]FMAU. Following incubation and removal of media, the cells were washed with phosphate-buffered saline (PBS, 3x10 mL) and treated with 0.3N perchloric acid. The acidic mixtures were cooled to 4°C for 10 min, centrifuged for 1 min at 14,000 rpm and the supernatant was separated. The cell pellets were washed twice with PCA (1 mL), centrifuged, and the acid soluble fractions, washings, and cell pellets were treated with complete counting scintillation cocktail. Radioactivity was counted in a liquid scintillation counter.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60145502
Created by
admin on Sat Dec 16 05:40:26 GMT 2023 , Edited by admin on Sat Dec 16 05:40:26 GMT 2023
|
PRIMARY | |||
|
O24SW9A8X6
Created by
admin on Sat Dec 16 05:40:26 GMT 2023 , Edited by admin on Sat Dec 16 05:40:26 GMT 2023
|
PRIMARY | |||
|
1027764-69-7
Created by
admin on Sat Dec 16 05:40:26 GMT 2023 , Edited by admin on Sat Dec 16 05:40:26 GMT 2023
|
PRIMARY | |||
|
25024028
Created by
admin on Sat Dec 16 05:40:26 GMT 2023 , Edited by admin on Sat Dec 16 05:40:26 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD